In Vivo Antibacterial Activities of Sanfetrinem Cilexetil, a New Oral Tricyclic Antibiotic
AUTOR(ES)
Tamura, Shinobu
FONTE
American Society for Microbiology
RESUMO
The in vivo antibacterial activities of a new oral trinem, sanfetrinem cilexetil (a prodrug of sanfetrinem), were evaluated in comparison with those of cefdinir and amoxicillin. Sanfetrinem cilexetil showed potent efficacy against experimental murine septicemia caused by Staphylococcus aureus, Streptococcus pyogenes, and Escherichia coli and against murine respiratory infections caused by Streptococcus pneumoniae. Likewise, in murine models of respiratory infection by penicillin-susceptible and penicillin-resistant S. pneumoniae, sanfetrinem cilexetil was more effective than amoxicillin in reducing the number of bacteria in infected lungs. These results were reflected in its potent in vitro activity and high levels in plasma.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=105698Documentos Relacionados
- In Vitro and In Vivo Antibacterial Activities of DW286, a New Fluoronaphthyridone Antibiotic
- In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
- In vitro and in vivo antibacterial activities of S-1090, a new oral cephalosporin.
- In vitro and in vivo antibacterial activities of CS-807, a new oral cephalosporin.
- In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.
